secwatch.observer — SEC 8-K summary
======================================

Issuer:     10x Genomics, Inc. (TXG)
CIK:        0001770787
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001770787-25-000048
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

10x Genomics Q2 revenue down 5% ex-litigation; net income $34.5M; acquires Scale Bio for $30M
--------------------------------------------------------------------------------

- Total revenue $172.9M including $27.3M patent settlement; adjusted revenue $145.6M (-5% YoY).
- GAAP net income $34.5M vs net loss $37.9M YoY; operating income $30.1M.
- Gross margin 72% vs 68% YoY; ex-license/royalty gross margin 67%.
- Q3 2025 revenue guidance $140M-$144M, reflecting ~$4M China pull-forward.
- Agreement to acquire Scale Biosciences for $30M upfront cash/stock plus milestone contingent consideration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1770787/000177078725000048/0001770787-25-000048-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1770787/000177078725000048/txg-20250807.htm
  HTML page:      https://secwatch.observer/filing/0001770787-25-000048

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer